Top

News & Events

Client News

Client News

National Care Group grows presence in County Durham with acquisition of Abbeyvale Care Centre

Accrington, UK – National Care Group (“NCG”), a leading provider of care and support services, announces the acquisition of the Abbeyvale Care Centre (“Abbeyvale”). Financial details of the deal were not disclosed.

Read more »

Consort Medical plc: Doubts Over Data Security Denting Smart Inhaler Potential?

Cambridge, UK – As many as 800 asthma deaths a year in the UK could be prevented by a new generation of ‘smart inhalers’, however, data concerns could be holding back roll out, says medical device developer and manufacturer, Bespak.

Read more »

Forbion Co-leads $54m Series A Financing in newly formed Gotham Therapeutics

Naarden, The Netherlands, and Munich, Germany, – Forbion, a leading European life sciences venture capital firm, today announces that it invested $15 million in the $54 million Series A financing in Gotham Therapeutics, a newly formed biotechnology company developing a novel drug class targeting RNA-modifying proteins.

Read more »

New PBS-Only Antibodies Enable More Flexible Research

Cambridge, UK – Abcam’s new phosphate buffered saline (PBS)-only recombinant antibodies are free from preservatives and stabilising agents, offering improved flexibility for researchers conducting more complex experiments.

Read more »

National Care Group completes acquisition of Cleveland House

Accrington, UK – National Care Group (“NCG”), a leading provider of care and support services, announces the acquisition of the Cleveland House business in Broadstairs, Kent. Financial details of the deal were not disclosed.

Read more »

Aglaris Appoints New CEO to Drive Commercialisation of Ground-breaking Cell-based Therapy Manufacturing System

Madrid and London Aglaris Ltd. today announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately.

Read more »

European Society for Medical Oncology President joins Imugene Scientific Advisory Board

Sydney, Australia - Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced the appointment of Dr Josep Tabernero, the President of the European Society for Medical Oncology, to its Scientific Advisory Board.

Read more »

BioForward - The 'Roadmap for Growth' Life Sciences Event

04 October 2018
BioForward - The 'Roadmap for Growth' Life Sciences Event
Birmingham, UK

Read more »

European Facility Updates from Consort Medical

Hemel Hempstead, UK – Consort Medical, Aesica CDMO Services, announces key facility updates for manufacturing and packaging solutions at both its Pianezza and Monheim sites.

Read more »

Feedback plc trading update – commercial progress and US market strategy

Cambridge, UK: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces a trading update for the year ended 31 May 2018 and the period to 30 September 2018. The Company is seeing improving trading conditions following a year of structural change and investment.

Read more »

Leading Pharma Executive Kate Hilyard Joins Healx to Drive the Integration of AI with Drug Discovery for Rare Diseases

Cambridge, UK – Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announced the appointment of Kate Hilyard PhD as Chief Operating Officer (COO).

Read more »

Forbion Closes Oversubscribed Fourth Life Sciences VC Fund at EUR 360 million

Naarden, The Netherlands, and Munich, Germany – Forbion, a leading European life science venture capital firm, has today announced the final close of its new flagship fund, Forbion IV. The oversubscribed fund closed at EUR 360 million in capital commitments, significantly above its original target of EUR 250 million.

Read more »

DNAe Wins Inaugural 2018 Medtech Insight Top Innovator Award

London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, was named ‘Most Innovative Team or Innovator of the Year’ at the inaugural 2018 Medtech Insight Awards.

Read more »

Evaluate Ltd: Worldwide medtech sales forecast to reach $595 billion by 2024, with a CAGR of 5.6%, anchored by familiar players

LONDON, BOSTON, TOKYO — The global medtech industry is forecast to grow at a CAGR of 5.6% from 2017 to 2024 and reach $595 billion in sales by 2024, according to the latest report from Evaluate Ltd. Medtronic was the leading medtech company in 2017 with sales of $30 billion, and is forecast to retain the crown in 2024 with sales of nearly $39 billion. Of the remaining top five companies in 2017, Johnson & Johnson, Abbott Laboratories and Siemens Healthineers are forecast to retain their places in 2024; however, Becton Dickinson jumps three spots to edge out Phillips and claim the number five spot following its purchase of C.R. Bard.

Read more »

Cell Medica: First neuroblastoma patient successfully dosed with innovative CAR therapy utilizing natural killer T cells (CAR-NKT)

HOUSTON and LONDON – Cell Medica announces the treatment of the first patient world-wide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma. This is the first time an engineered NKT cell therapy has been used in humans. Cell Medica is a clinical-stage biopharmaceutical company that is transforming the treatment of solid and hematological cancer by developing the next generation of CAR therapies.

Read more »

Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.

Read more »

Abzena announces a research and licence agreement with Tmunity Therapeutics

Cambridge, UK – Abzena, plc (AIM: ABZA, Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed an antibody humanisation agreement with Tmunity Therapeutics (Tmunity), a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen Receptor T Cell (CAR-T) therapies for the treatment of solid and hematological cancers.

Read more »

SkinBioTherapeutics plc: Human study commenced

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health, confirms that it has commenced its human study being carried out on its SkinBiotix® technology.

Read more »

Xellia Pharmaceuticals Opens North American Commercial Office in Chicago Ahead of Launching Value-Added Anti-Infective Injectable Drug Products

Copenhagen, Denmark - Xellia Pharmaceuticals (Xellia or the Company), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections, today announced that it has opened a new office in Buffalo Grove, near Chicago, Illinois to accommodate the Company’s expanding North American commercial organization.

Read more »

Congenica Announces Market Access Partnership with Digital China Health to Enable Genomic Medicine in the Chinese market

Cambridge, United Kingdom – Congenica, the global diagnostic decision support platform provider, today announced it has entered into an agreement with a new strategic partner Digital China Health Technologies Cooperation Limited (DCHealth), further extending Congenica’s commitment to the Chinese market.

Read more »

Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment

SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced the Phase 1b clinical trial of its HER-Vaxx cancer vaccine in HER-2 gastric cancer patients had completed recruitment.

Read more »

Crescendo Biologics Strengthens its Management with the Appointment of Dr Pavel Pisa as Chief Medical Officer

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Pavel Pisa, MD, PhD, has been appointed as Chief Medical Officer of the Company with immediate effect.

Read more »

F-star Appoints Nessan Bermingham as Chairman of its Board of Directors

Cambridge, UK – F-star, a biopharmaceutical company developing novel bispecific antibodies, today announces the appointment of Nessan Bermingham, Ph.D. as Chairman of its Board of Directors. Nessan succeeds John Edwards who has been F-star’s Chairman for seven years and will remain as a non-executive director.

Read more »

TexRAD® ordered by Samsung Medical Centre in South Korea

Cambridge, UK: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company Feedback Medical Ltd has received an order from its South Korean distributor for TexRAD®, its patented image texture analysis technology, for the Samsung Medical Centre in Seoul.

Read more »

Biopharma Company Arecor raises £6m for revolutionary diabetes treatments

Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures.  BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures.

Read more »